Johnson & Johnson Aktie
WKN: 853260 / ISIN: US4781601046
02.10.2024 16:31:17
|
JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer
(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months compared to Enzalutamide in patients with metastatic castration-sensitive prostate cancer.
The analysis found that patients who initiated Erleada as their first androgen receptor pathway inhibitor had a statistically significant 23 percent reduction in their risk of death at 24 months compared to those on Enzalutamide.
"Erleada is the only ARPI to demonstrate a survival benefit as early as 22 months, as seen in the TITAN study," noted Luca Dezzani, U.S. Vice President, Medical Affairs, Solid Tumors, Johnson & Johnson Innovative Medicine.
Currently, JNJ's stock is trading at $161.06, down 0.57 percent on the New York Stock Exchange.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Johnson & Johnsonmehr Nachrichten
19.03.25 |
NYSE-Handel: Börsianer lassen Dow Jones schlussendlich steigen (finanzen.at) | |
19.03.25 |
Freundlicher Handel: Dow Jones im Plus (finanzen.at) | |
19.03.25 |
Pluszeichen in New York: So steht der Dow Jones am Mittag (finanzen.at) | |
19.03.25 |
Dow Jones 30 Industrial-Papier Johnson Johnson-Aktie: So viel hätte eine Investition in Johnson Johnson von vor 3 Jahren gekostet (finanzen.at) | |
19.03.25 |
Gute Stimmung in New York: Dow Jones legt zum Handelsstart zu (finanzen.at) | |
18.03.25 |
Schwacher Wochentag in New York: Dow Jones legt schlussendlich den Rückwärtsgang ein (finanzen.at) | |
18.03.25 |
Dow Jones aktuell: Dow Jones am Dienstagnachmittag in Rot (finanzen.at) | |
18.03.25 |
Minuszeichen in New York: So steht der Dow Jones mittags (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 150,00 | -1,06% |
|